Product Description
Mechanisms of Action: CYP24 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Topical,Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: OPKO Health
Company Location: MIAMI FL 33137
Company CEO: Phillip Frost
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Kidney Failure, Chronic|Hyperparathyroidism, Secondary|Psoriasis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2007 | P2 |
Withdrawn |
Kidney Failure, Chronic|Hyperparathyroidism, Secondary |
2013-07-01 |
|
CTA018-CL-2002 | P2 |
Completed |
Kidney Failure, Chronic|Hyperparathyroidism, Secondary |
2010-02-01 |
|
CTA018-CL-2001 | P2 |
Completed |
Psoriasis |
2007-05-01 |